Navigation Links
David Lichtenstein: Biotechnology is Rich Area for Investment
Date:10/30/2012

NEW YORK, Oct. 30, 2012 /PRNewswire/ -- As many scientists and researchers are aware, biology entails an incredibly complex series of mechanisms and processes that still amaze intelligent minds today. While these biological systems have shaped the world, the application of modern biotechnology has only existed for approximately for three decades. According to a recent FundWeb article, this year marks the 30th anniversary of the "first biotechnology drug approved for human medical use," known as Humulin, "a genetically engineered version of natural human insulin for the treatment of diabetes." Since 1982, biotechnology has seeped its way into modern science and popular applications, which has led many to believe that biotechnology is the next "technology super-cycle." David Lichtenstein, biotechnology supporter and BrainStorm Cell Therapeutics investor, agrees that the science certainly holds the potential to change culture and the way humans live and solve problems.

David Lichtenstein states, "It is amazing to look back at the last 30 years — a small period in terms of scientific development — and realize just how far biotechnology has come. I expect these applications to become more present in our society, improving every facet of daily life." According to the article, such varied use of biotechnology has been witnessed since the original introduction of Humulin. It states, "Roughly two-thirds of all new drugs approved by the FDA have been discovered and/or developed by a biotechnology company at some stage." In addition to medical use, biotechnology has encouraged significant changes in agriculture and industrial manufacturing."

According to the article, financial analysts believe that biotechnology holds the potential for creating the next major socio-economic era in modern culture. It explains that such possibility for growth opens up a wide variety of investment opportunities in biotechnology. However, few have committed to investing in the science. Having already made significant investments in the field of biotechnology, David Lichtenstein knows that the industry holds promise. At BrainStorm Cell Therapeutics alone, there are projects that focus on repairing ALS, Multiple Sclerosis and Parkinson's disease through stem cell therapy.

David Lichtenstein concludes, "As far as investment strategies go, biotechnology is one field that is new, exciting and offers opportunity for long-term profit. After close examination, I believe wary investors may change their mind about investing in this incredible field of science."

ABOUT:

David Lichtenstein is a supporter of the growth of biotechnology and has become a major investor in the innovative science. He is currently an investor in BrainStorm Cell Therapeutics, a biotechnology company that develops adult stem cell therapies to resolve medical issues associated with severe neurodegenerative disorders including ALS, Multiple Sclerosis and Parkinson's disease. In addition, David Lichtenstein has proven his worth as an investment strategist, having steadily built the Lightstone Group since 1988. As chairman and CEO of the Lightstone Group, David Lichtenstein has carefully developed a diverse portfolio of properties allowing the company to become of the most widespread and successful privately held real estate companies in the United States of America.

 


'/>"/>
SOURCE David Lichtenstein
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Renowned Operations and Supply Chain Expert Dr. David Simchi-Levi Joins OPS Rules
2. Maine Center for Creativity Selects Glenn Close and David Shaw to Receive Inaugural Maine Creative Industry Award
3. China Biologic Products Names Chairman David Gao to Additional Post of CEO
4. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
5. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
6. Germany Prioritizes Medical Biotechnology with New Initiatives
7. Biomass characterization technology research highlighted in Industrial Biotechnology journal
8. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
9. Global Marine Biotechnology Industry
10. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
11. India Biotechnology in India Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... , ... October 10, 2017 , ... Dr. Bob Harman, ... his local San Diego Rotary Club. The event entitled “Stem Cells ... and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human ...
Breaking Biology Technology:
(Date:8/15/2017)... 15 2017   ivWatch LLC , a medical device company ... today announced receipt of its ISO 13485 Certification, the global standard ... Organization for Standardization (ISO®). ... Model 400 Continuous Monitoring device for the early detection of IV ... "This is an important milestone for ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
Breaking Biology News(10 mins):